Related Experiment Video
Updated: Mar 31, 2026

Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide
Published on: May 12, 2023
Molecular Pathways: Fatty Acid Synthase
Suzanne F Jones1, Jeffrey R Infante2
1Sarah Cannon Research Institute, Nashville, Tennessee.
Abstract:
Therapies that target tumor metabolism represent a new horizon in anticancer therapies. In particular, cancer cells are dependent on the generation of lipids, which are essential for cell membrane synthesis, modification of proteins, and localization of many oncogenic signal transduction enzymes. Because fatty acids are the building blocks of these important lipids, fatty acid synthase (FASN) emerges as a unique oncologic target. FASN inhibitors are being studied preclinically and beginning to transition to first-in-human trials. Early generation FASN inhibitors have been studied preclinically but were limited by their pharmacologic properties and side-effect profiles. A new generation of molecules, including GSK2194069, JNJ-54302833, IPI-9119, and TVB-2640, are in development, but only TVB-2640 has moved into the clinic. FASN inhibition, either alone or in combination, holds promise as a novel therapeutic approach for patients with cancer.
Insights
Targeting tumor metabolism with fatty acid synthase (FASN) inhibitors is a promising new cancer therapy. Newer FASN inhibitors are advancing, with some entering clinical trials for cancer treatment.
Area of Science:
- Oncology
- Cancer Metabolism
- Drug Development
Background:
- Cancer cells rely on lipid synthesis for growth and survival.
- Fatty acid synthase (FASN) is crucial for producing lipids, making it a key oncologic target.
- Targeting tumor metabolism represents a novel therapeutic strategy in oncology.
Purpose of the Study:
- To review the role of FASN in cancer.
- To discuss the development of FASN inhibitors as anticancer therapies.
- To highlight the potential of FASN inhibition in clinical settings.
Main Methods:
- Review of preclinical and clinical studies on FASN inhibitors.
- Analysis of the pharmacologic properties and side-effect profiles of FASN inhibitors.
- Identification of novel FASN inhibitors in development.
Main Results:
- Early-generation FASN inhibitors faced limitations in pharmacology and side effects.
- A new generation of FASN inhibitors, including TVB-2640, is under investigation.
- TVB-2640 is the only FASN inhibitor that has advanced to clinical trials.
Conclusions:
- FASN inhibition is a promising therapeutic approach for cancer patients.
- Combination therapies involving FASN inhibitors may offer enhanced efficacy.
- Further clinical investigation of FASN inhibitors is warranted.
More Related Videos
09:27Functional Complementation Analysis FCA: A Laboratory Exercise Designed and Implemented to Supplement the Teaching of Biochemical Pathways
Published on: June 24, 2016
11:03Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
Published on: September 9, 2021
Related Concept Videos
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Amino Acid Biosynthetic Pathways
Biosynthesis of Lipids
Respiration Pathways
Lipid Catabolism
Synthesis of Phosphatidylcholine in the ER Membrane
The major components of all eukaryotic cell...